Injections should only be administered by a qualified medical professional
HDL-C concentration is not a predictor of cardiovascular risk or a target of lipid-lowering therapy
Invert vial & insert needle Step 3
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
In the SURMOUNT-1 trial, people treated with tirzepatide lost up to 22.5% of their body weight over 72 weeks , making it even more effective than semaglutide (NEJM tirzepatide study)
Individuals taking Semaglutide may encounter severe Semaglutide side effects mentioned earlier, but the possible transfer into breast milk can affect infants, such as: Hypoglycemia Gastrointestinal Issues Growth Impairment Breastfeeding mothers who need to manage their diabetes or chronic weight loss may opt for insulin, metformin, dietary adjustments, and consistent physical activity